Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

Summary

Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis

Timeline

Start

2015-09-04

Primary completion

2017-01-17

Completion

2017-08-29

Outcome

Missed primary endpoint

registry analysis (superiority test); DSXS Topical Product vs Placebo Topical Product; p = 0.3353; z-test, 2-tailed NCT02595073 ↗

Drugs

Indications